Overview

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Status:
Recruiting

Trial end date:
2031-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Sciences Ireland UC

Treatments:

Reverse Transcriptase Inhibitors
Rilpivirine